Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 4/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.36 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046459 | 0.79 | ALDH1A1 (0.40) | KMT2AMEN1TDP1ALDH1A1TSHR | |
| SCHEMBL29890913 | 0.79 | ALDH1A1 (0.40) | KMT2AMEN1TDP1ALDH1A1TSHR | |
| SCHEMBL11278823 | 0.76 | NOX1 (0.53) | KMT2ALMNAMEN1TDP1THRB | |
| SCHEMBL9935195 | 0.76 | MEN1 (0.40) | KMT2ALMNAMEN1TDP1THRB | |
| Thianthrene SCHEMBL31297739 | 0.75 | LMNA (0.54) | KMT2ALMNAMEN1TDP1THRB | |
| SCHEMBL7392294 | 0.73 | MAOA (0.56) | KMT2ALMNAMEN1TDP1THRB | |
| SCHEMBL9031609 | 0.71 | ALOX5 (0.43) | KMT2AMEN1TDP1ALDH1A1ALOX5 | |
| SCHEMBL4795404 | 0.71 | — | — | |
| SCHEMBL9590157 | 0.71 | HDAC6 (0.41) | KMT2ALMNAMEN1TDP1THRB | |
| SCHEMBL8582075 | 0.71 | ALOX5 (0.37) | KMT2ALMNAMEN1ALDH1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106957317-B | Novel pyrazole derivatives | 持田制药株式会社 | 2019-12-31 | — | — | CN | disclosed |
| CN-106749290-B | It is a kind of based on the oxidation compound of thioxanthone, preparation method and applications | 中节能万润股份有限公司 | 2019-02-26 | — | — | CN | disclosed |
| US-9777000-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2017-10-03 | — | — | US | disclosed |
| CN-107184467-A | A kind of hair care exterior-applied article being made of Lignum Xanthoceratis extract and preparation method thereof | 山西双林富农林开发有限公司 | 2017-09-22 | — | — | CN | disclosed |
| CN-106749290-A | A kind of compound, preparation method and applications based on oxidation thioxanthone | 中节能万润股份有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-20160347751-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-12-01 | — | — | US | disclosed |
| US-9458157-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9453015-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9440970-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| CN-105250395-A | Traditional Chinese medicine composition for treating cerebral hemorrhage sequela, preparing method thereof and application thereof | XIE XIANDE | 2016-01-20 | — | — | CN | disclosed |
| EP-2518064-A1 | NOVEL ARYL UREA DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2518060-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| CN-102630858-A | Compound pig feed containing Chinese herbal medicine | QINGDAO HEMEI FEED CO LTD | 2012-08-15 | — | — | CN | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| US-4976771-A | ALSO PLANT GROWTH REGULATORS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-12-11 | — | — | US | disclosed |
| US-4857545-A | PLANT GROWTH REGULATORS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-08-15 | — | — | US | disclosed |
| EP-0270252-A2 | Derivatives of propenoic acids used in agriculture | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-06-08 | — | — | EP | disclosed |
| CN-85105797-A | The preparation of antimicrobial compounds | — | 1986-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347751-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | KMT2A 2932/4885LMNA 3655/4885MEN1 4110/4885 |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | KMT2A 3600/4885LMNA 4218/4885MEN1 3552/4885 |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | KMT2A 3915/4885LMNA 4435/4885MEN1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.